News

Patients achieved excellent new hair growth and strength when combining PRP with drug therapy after hair transplantation surgery.

The study is set to begin enrollment later this year.

VSLS laser technology offers safe, effective treatment for solar lentigines, minimizing PIH and recurrence with advanced cooling and precision targeting.

Australian researchers found 5-FU to be the cheapest AK treatment, compared to imiquimod and MAL-photodynamic therapy.

A novel study assessed the potential of 2 AI platforms in providing accurate information to patients with HS.

Research suggested acne is primarily inflammatory, occurring even in unaffected skin, redefining its pathophysiology.

ENS-002 targets S. aureus in atopic dermatitis.

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

Benjamin Lockshin, MD, FAAD, discussed combining biologics with topical innovations like tapinarof and roflumilast to address plaque psoriasis treatment gaps.

The company’s phase 3 trials show JNJ-2113 significantly improves skin clearance and tolerability for patients with moderate to severe psoriasis.

Patients with moderate to severe atopic dermatitis saw the most improvement after taking 600 mg of tozorakimab.

Patients treated with dupilumab saw substantial healing, with over 70% achieving >50% lesion improvement in 24 weeks.

2-year data show 75.7% of TNFi-IR patients maintained ACR50, 80.6% achieved PASI100, and pain and fatigue improvements were sustained.

November's cover feature highlights the revolutionary role of artificial intelligence in the development of zasocitinib for the treatment of psoriasis.

A recent analysis found primary closure in HS surgery has higher recurrence rates, while secondary intention healing avoids complications but prolongs recovery.

Higher stress hyperglycemia ratios are linked to elevated mortality risk in psoriasis, highlighting its systemic nature and need for intensive care.

The ILDS has named 6 young dermatologists from around the world as recipients of the 2025 Young Dermatologists International Achievement Awards for their contributions to dermatology.

In a Dermatology Times Case-Based Peer Perspective event, Terry Faleye, MPAS, PA-C, reviewed 2 cases of patients with vitiligo to discuss innovative treatments and emotional challenges with disease management.

You're allowed to be proud of yourself, no matter how long you have been in practice, writes our Fall Editor in Chief Raj Chovatiya, MD, PhD.

Catch up on coverage from the final day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.

At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted innovative strategies for managing complex rosacea cases, the importance of combination approaches, and a slowing treatment pipeline.

At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted the superiority of branded acne therapies, the necessity of tailored regimens, and the value of structured PA education.

Take this quiz to see if you are leveraging the latest research in acne treatment.

At the SDPA Fall Conference, Miranti emphasized the importance of targeted, comprehensive acne therapies and inspired attendees to embrace pediatric dermatology as a rewarding subspecialty.

Catch up on coverage from the third day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.

At the 2024 SDPA Fall Conference, Audrey Rutherford, MD, discussed the critical role of vulvar biopsies in identifying cancer and other conditions to improve patient outcomes for underdiagnosed vulvar conditions.

Zirwas spoke with Dermatology Times to share the top clinical pearls and key takeaways from his discussion on contact dermatitis.

At the 2024 SDPA Fall Conference, Renata Block, MMS, PA-C, emphasized the power of membership, tailored education, interdisciplinary collaboration, and advocacy in shaping the future of dermatology to improve patient outcomes.

Jane Mast, PhD, DMSc, MPAS, shares her thoughts on the award, being a Derm PA, and dermatology.

Post-hoc analysis demonstrated secukinumab's efficacy in addressing both HS and HS-related psychiatric symptoms.